Holen Sie sich die Stockscreener-App
1.54
4.76%
0.07
Vorhandelsmarkt:
1.60
0.06
+3.90%
Schlusskurs vom Vortag:
$1.47
Offen:
$1.47
24-Stunden-Volumen:
627.72K
Relative Volume:
0.53
Marktkapitalisierung:
$97.16M
Einnahmen:
$139.77M
Nettoeinkommen (Verlust:
$-97.62M
KGV:
-0.9747
EPS:
-1.58
Netto-Cashflow:
$-61.71M
1W Leistung:
+3.36%
1M Leistung:
+17.56%
6M Leistung:
-50.00%
1J Leistung:
-71.16%
1-Tages-Spanne:
$1.47
$1.58
1-Wochen-Bereich:
$1.47
$1.605
52-Wochen-Spanne:
$0.9897
$5.77
Macrogenics Inc Stock (MGNX) Company Profile
Firmenname
Macrogenics Inc
Sektor
Branche
Telefon
301-251-5172
Adresse
9704 MEDICAL CENTER DRIVE, Rockville, MD
Vergleichen Sie MGNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.54 | 94.00M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-31 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-05-10 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-04-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-03-04 | Bestätigt | BTIG Research | Buy |
| 2024-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-22 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-11-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-02-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-04 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Hochstufung | Barclays | Underweight → Overweight |
| 2020-12-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2019-12-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Guggenheim | Neutral |
| 2019-02-07 | Hochstufung | Citigroup | Sell → Buy |
| 2019-02-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-02-06 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-12-10 | Herabstufung | Raymond James | Outperform → Underperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-05-31 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-31 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Macrogenics Inc Aktie (MGNX) Neueste Nachrichten
Is MacroGenics Inc. a good long term investmentPhenomenal returns - Autocar Professional
Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - ACCESS Newswire
MacroGenics Inc. Stock Analysis and ForecastExplosive capital appreciation - jammulinksnews.com
What analysts say about MacroGenics Inc. stockSkyrocketing investment returns - jammulinksnews.com
Why MacroGenics Inc. stock attracts strong analyst attentionFree Signals Group - Newser
What drives MacroGenics Inc. stock priceExplosive earning power - jammulinksnews.com
What makes MacroGenics Inc. stock price move sharplyFree Expert-Led Investment Training - Newser
Is MacroGenics Inc. stock a good hedge against inflationHigh Probability Setups - Newser
How MacroGenics Inc. stock performs during market volatilityLong Term Low Risk Growth - Newser
MacroGenics And 2 Other Promising Penny Stocks To Consider - Yahoo Finance
Positive week for MacroGenics, Inc. (NASDAQ:MGNX) institutional investors who lost 66% over the past year - simplywall.st
MacroGenics (NASDAQ:MGNX) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) is largely controlled by institutional shareholders who own 71% of the company - Yahoo Finance
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics - ACCESS Newswire
Investors who lost money on MacroGenics, Inc. should contact Levi & Korsinsky about an ongoing investigationMGNX - ACCESS Newswire
Investors who Lost Money on MacroGenics, Inc. (MGNX) Should Contact Levi & Korsinsky About Pending Class ActionMGNX - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of MacroGenics, Inc. (MGNX) Shareholders - ACCESS Newswire
MacroGenics, Inc.(NasdaqGS: MGNX) dropped from Russell 2000 Index - MarketScreener
MacroGenics, Inc.(NasdaqGS: MGNX) dropped from Russell 3000E Value Index - MarketScreener
MacroGenics Advances Cancer Treatment with MGC026 Study Update - TipRanks
Exchange Traded Concepts LLC Raises Stock Position in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
A Closer Look at Macrogenics Inc (MGNX) Stock Gains - investchronicle.com
MacroGenics (NASDAQ:MGNX) Shares Pass Below Two Hundred Day Moving Average – Time to Sell? - Defense World
MacroGenics’ SWOT analysis: biotech firm’s stock faces pivotal year ahead By Investing.com - Investing.com India
MacroGenics’ SWOT analysis: biotech firm’s stock faces pivotal year ahead - Investing.com
MacroGenics secures $70M from Sagard in royalty deal By Investing.com - Investing.com Nigeria
MacroGenics: Working On That Road To Recovery (NASDAQ:MGNX) - Seeking Alpha
MacroGenics lands $70M 'infusion of cash' to advance clinical programs - The Business Journals
MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Traders Buy High Volume of MacroGenics Call Options (NASDAQ:MGNX) - Defense World
MacroGenics (MGNX) Secures $70M Upfront Payment in Royalty Deal - GuruFocus
MacroGenics signs financial deal with Sagard for retifanlimab - Seeking Alpha
Finanzdaten der Macrogenics Inc-Aktie (MGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):